GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China NT Pharma Group Co Ltd (HKSE:01011) » Definitions » PE Ratio (TTM)

China NT Pharma Group Co (HKSE:01011) PE Ratio (TTM) : At Loss (As of Apr. 02, 2025)


View and export this data going back to 2011. Start your Free Trial

What is China NT Pharma Group Co PE Ratio (TTM)?

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2025-04-02), China NT Pharma Group Co's share price is HK$0.248. China NT Pharma Group Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-0.76. Therefore, China NT Pharma Group Co's PE Ratio (TTM) for today is At Loss.


The historical rank and industry rank for China NT Pharma Group Co's PE Ratio (TTM) or its related term are showing as below:

HKSE:01011' s PE Ratio (TTM) Range Over the Past 10 Years
Min: At Loss   Med: 23.68   Max: 1254.17
Current: At Loss


During the past 13 years, the highest PE Ratio (TTM) of China NT Pharma Group Co was 1254.17. The lowest was 0.00. And the median was 23.68.


HKSE:01011's PE Ratio (TTM) is ranked worse than
100% of 614 companies
in the Drug Manufacturers industry
Industry Median: 20.96 vs HKSE:01011: At Loss

China NT Pharma Group Co's Earnings per Share (Diluted) for the six months ended in Jun. 2024 was HK$0.00. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-0.76.

As of today (2025-04-02), China NT Pharma Group Co's share price is HK$0.248. China NT Pharma Group Co's EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-0.16. Therefore, China NT Pharma Group Co's PE Ratio without NRI for today is At Loss.

During the past 13 years, China NT Pharma Group Co's highest PE Ratio without NRI was 436.23. The lowest was 0.00. And the median was 20.34.

China NT Pharma Group Co's EPS without NRI for the six months ended in Jun. 2024 was HK$0.00. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-0.16.

China NT Pharma Group Co's EPS (Basic) for the six months ended in Jun. 2024 was HK$0.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-0.76.


China NT Pharma Group Co PE Ratio (TTM) Historical Data

The historical data trend for China NT Pharma Group Co's PE Ratio (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China NT Pharma Group Co PE Ratio (TTM) Chart

China NT Pharma Group Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PE Ratio (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

China NT Pharma Group Co Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
PE Ratio (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Competitive Comparison of China NT Pharma Group Co's PE Ratio (TTM)

For the Drug Manufacturers - Specialty & Generic subindustry, China NT Pharma Group Co's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China NT Pharma Group Co's PE Ratio (TTM) Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China NT Pharma Group Co's PE Ratio (TTM) distribution charts can be found below:

* The bar in red indicates where China NT Pharma Group Co's PE Ratio (TTM) falls into.


;
;

China NT Pharma Group Co PE Ratio (TTM) Calculation

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

China NT Pharma Group Co's PE Ratio (TTM) for today is calculated as

PE Ratio (TTM)=Share Price/Earnings per Share (Diluted) (TTM)
=0.248/-0.764
=At Loss

China NT Pharma Group Co's Share Price of today is HK$0.248.
For company reported semi-annually, China NT Pharma Group Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-0.76.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PE Ratio (TTM)=Market Cap /Net Income

There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


China NT Pharma Group Co  (HKSE:01011) PE Ratio (TTM) Explanation

The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.

If a company loses money, the PE Ratio (TTM) becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.

Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio (TTM) measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .

PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).


China NT Pharma Group Co PE Ratio (TTM) Related Terms

Thank you for viewing the detailed overview of China NT Pharma Group Co's PE Ratio (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


China NT Pharma Group Co Business Description

Traded in Other Exchanges
N/A
Address
198 Wellington Street, 28th Floor, The Wellington, Sheung Wan, Hong Kong, HKG
China NT Pharma Group Co Ltd is a technology-based pharmaceutical company. It is engaged in research and development, production, and sale of private-label drugs, as well as the provision of pharmaceutical marketing and promotion services in China. It focused on the research, development, production, and sales of orthopedic, psychiatric, and oncology drugs. The company operates in a single segment of Proprietary product production and sales. The company earns the majority of its revenue from the domestic market. The Group's revenue from an external customer was derived solely from its operations in the PRC.
Executives
Ieong Chong Mang
Golden Base Investment Limited
Wang Minzhi 2101 Beneficial owner
Shum Ning
Chin Yu
Ng Tit
Ieong Iat 2101 Beneficial owner

China NT Pharma Group Co Headlines

No Headlines